A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib in Patients With Recurrent Ovarian Cancer or Triple Negative Breast Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This PHASE1 trial investigates Ovarian Cancer and Triple Negative Breast Cancer and is currently completed. Jiangsu HengRui Medicine Co., Ltd. leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Completed PHASE1
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
▶ Show 5 earlier versions
-
Oct 2021 — Apr 2022 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
-
Jul 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE1
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
- Peking University Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .